Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA, Borgman AS, Winn ME, Dykema KJ, Webb CP, MacKeigan JP, Duesbery NS, Nickoloff BJ, Monks NR.

Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015.

2.

Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation.

Berezovsky AD, Poisson LM, Cherba D, Webb CP, Transou AD, Lemke NW, Hong X, Hasselbach LA, Irtenkauf SM, Mikkelsen T, deCarvalho AC.

Neoplasia. 2014 Mar;16(3):193-206, 206.e19-25. doi: 10.1016/j.neo.2014.03.006. Epub 2014 Apr 13.

3.

Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.

Monsma DJ, Cherba DM, Richardson PJ, Vance S, Rangarajan S, Dylewski D, Eugster E, Scott SB, Beuschel NL, Davidson PJ, Axtell R, Mitchell D, Lester EP, Junewick JJ, Webb CP, Monks NR.

Pediatr Blood Cancer. 2014 Sep;61(9):1570-7. doi: 10.1002/pbc.25039. Epub 2014 Mar 31.

PMID:
24687871
4.

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.

Peacock JD, Cherba D, Kampfschulte K, Smith MK, Monks NR, Webb CP, Steensma M.

J Transl Med. 2013 Sep 17;11:213. doi: 10.1186/1479-5876-11-213.

5.

A multi-site feasibility study for personalized medicine in canines with osteosarcoma.

Monks NR, Cherba DM, Kamerling SG, Simpson H, Rusk AW, Carter D, Eugster E, Mooney M, Sigler R, Steensma M, Grabinski T, Marotti KR, Webb CP.

J Transl Med. 2013 Jul 1;11:158. doi: 10.1186/1479-5876-11-158.

6.

Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.

Mooney M, Bond J, Monks N, Eugster E, Cherba D, Berlinski P, Kamerling S, Marotti K, Simpson H, Rusk T, Tembe W, Legendre C, Benson H, Liang W, Webb CP.

PLoS One. 2013 Apr 4;8(4):e61088. doi: 10.1371/journal.pone.0061088. Print 2013.

7.

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue.

Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, Ishkin A, Nikolsky Y, Resau JH, Sigler R, Nickoloff BJ, Webb CP.

J Transl Med. 2012 Jun 18;10:125. doi: 10.1186/1479-5876-10-125.

8.

MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.

Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS.

PLoS One. 2011 Feb 18;6(2):e17165. doi: 10.1371/journal.pone.0017165.

9.

Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.

Melnik MK, Webb CP, Richardson PJ, Luttenton CR, Campbell AD, Monroe TJ, O'Rourke TJ, Yost KJ, Szczepanek CM, Bassett MR, Truszkowski KJ, Stein P, Van Brocklin MW, Davis AT, Bedolla G, Vande Woude GF, Koo HM.

Mol Cancer Ther. 2010 Aug;9(8):2423-9. doi: 10.1158/1535-7163.MCT-09-0854. Epub 2010 Aug 3.

10.

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.

Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson-Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring J, Honor D, Snook S, Lee J, Rossi P, Walker E, Mattes W.

Nat Biotechnol. 2010 May;28(5):455-62. doi: 10.1038/nbt.1625. Epub 2010 May 10.

PMID:
20458315
11.

Smoking initiation and nicotine dependence symptoms in Ukraine: findings from the Ukraine World Mental Health survey.

Webb CP, Bromet EJ, Tintle NL, Schwartz JE, Gluzman SF, Kostyuchenko S, Havenaar JM.

Public Health. 2007 Sep;121(9):663-72. Epub 2007 Jun 4.

12.

Discovery of cancer biomarkers through the use of mouse models.

Kuick R, Misek DE, Monsma DJ, Webb CP, Wang H, Peterson KJ, Pisano M, Omenn GS, Hanash SM.

Cancer Lett. 2007 Apr 28;249(1):40-8. Epub 2007 Feb 22. Review.

PMID:
17320282
13.

Gene expression in rat lacrimal gland duct cells collected using laser capture microdissection: evidence for K+ secretion by duct cells.

Ubels JL, Hoffman HM, Srikanth S, Resau JH, Webb CP.

Invest Ophthalmol Vis Sci. 2006 May;47(5):1876-85.

PMID:
16638994
14.

Epidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine World Mental Health survey.

Bromet EJ, Gluzman SF, Paniotto VI, Webb CP, Tintle NL, Zakhozha V, Havenaar JM, Gutkovich Z, Kostyuchenko S, Schwartz JE.

Soc Psychiatry Psychiatr Epidemiol. 2005 Sep;40(9):681-90. Epub 2005 Sep 20.

PMID:
16160752
15.

Epidemiology of heavy alcohol use in Ukraine: findings from the world mental health survey.

Webb CP, Bromet EJ, Gluzman S, Tintle NL, Schwartz JE, Kostyuchenko S, Havenaar JM.

Alcohol Alcohol. 2005 Jul-Aug;40(4):327-35. Epub 2005 Apr 11.

PMID:
15824065
16.

Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation.

Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, Kuick R, Giordano TJ, Gao W, Omenn GS, Webb CP, Hanash SM.

Mol Cancer Res. 2005 Mar;3(3):119-29.

17.

Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts.

Bromann PA, Korkaya H, Webb CP, Miller J, Calvin TL, Courtneidge SA.

J Biol Chem. 2005 Mar 18;280(11):10253-63. Epub 2005 Jan 5.

18.
19.

Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector.

Bromberg-White JL, Webb CP, Patacsil VS, Miranti CK, Williams BO, Holmen SL.

J Virol. 2004 May;78(9):4914-6.

20.

Treating juvenile offenders for marijuana problems.

Webb CP, Burleson JA, Ungemack JA.

Addiction. 2002 Dec;97 Suppl 1:35-45.

PMID:
12460127
21.

Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.

Haddad R, Lipson KE, Webb CP.

Anticancer Res. 2001 Nov-Dec;21(6B):4243-52. Review.

PMID:
11908677
22.

Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.

Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Vande Woude GF, Webb CP.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10722-7. Epub 2001 Sep 4.

23.

Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.

Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude GF, Knudsen BS.

Am J Pathol. 2001 Aug;159(2):579-90.

24.

Animal models for Ras-induced metastasis.

Webb CP, Vande Woude GF.

Methods Enzymol. 2001;333:318-29. No abstract available.

PMID:
11400348
25.

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.

Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH, Vande Woude GF.

Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4089-94. Epub 2001 Mar 20.

26.

Genes that regulate metastasis and angiogenesis.

Webb CP, Vande Woude GF.

J Neurooncol. 2000 Oct-Nov;50(1-2):71-87. Review.

PMID:
11245283
27.

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.

Cancer Res. 2000 Jan 15;60(2):342-9.

28.

MEK wars, a new front in the battle against cancer.

Duesbery NS, Webb CP, Vande Woude GF.

Nat Med. 1999 Jul;5(7):736-7. No abstract available.

PMID:
10395314
29.

The mutationally activated Met receptor mediates motility and metastasis.

Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14417-22.

30.

Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis.

Webb CP, Taylor GA, Jeffers M, Fiscella M, Oskarsson M, Resau JH, Vande Woude GF.

Oncogene. 1998 Oct 22;17(16):2019-25.

PMID:
9798673
31.

Decreased fibronectin expression in Met/HGF-mediated tumorigenesis.

Taylor GA, Jeffers M, Webb CP, Koo HM, Anver M, Sekiguchi K, Vande Woude GF.

Oncogene. 1998 Sep 3;17(9):1179-83.

32.

Signaling pathways in Ras-mediated tumorigenicity and metastasis.

Webb CP, Van Aelst L, Wigler MH, Vande Woude GF.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8773-8.

33.

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF.

Science. 1998 May 1;280(5364):734-7.

34.

Activating mutations for the met tyrosine kinase receptor in human cancer.

Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF.

Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50.

35.

C-Met signalling in an HGF/SF-insensitive variant MDCK cell line with constitutive motile/invasive behaviour.

Webb CP, Lane K, Dawson AP, Vande Woude GF, Warn RM.

J Cell Sci. 1996 Sep;109 ( Pt 9):2371-81.

36.

Supplemental Content

Support Center